On Biostatistics and Clinical Trials
CQ's web blog on the issues in biostatistics and clinical trials.
Showing posts with label
benefit/risk
.
Show all posts
Showing posts with label
benefit/risk
.
Show all posts
Saturday, June 19, 2021
About Controversial Approval of Biogen's Alzheimer Drug
›
Two weeks ago, the US Food and Drug Administration (FDA) approved aducanumab (brand name Aduhelm) as a treatment for Alzheimer's disease...
2 comments:
Monday, April 26, 2021
Within Patient Benefit-Risk Evaluation? Using Outcomes to Analyze Patients versus Using Patients to Analyze Outcomes?
›
In our daily life, benefit-risk evaluation is something we always do whether we realize it or not. Benefit-risk evaluation is especially cri...
›
Home
View web version
